原发性运动皮层受累与脑转移患者癫痫风险的关联
该回顾性队列研究纳入2003至2022年布里格姆妇女医院/丹娜法伯癌症研究院数据库中有脑转移影像学证据的患者,评估脑转移位于原发性运动皮层是否增加癫痫风险。结果显示原发性运动皮层受累与诊断时及诊断后癫痫风险升高相关,但鉴于回顾性设计,不推荐在临床试验外常规使用抗癫痫药物。
要点
- 脑转移位于原发性运动皮层患者诊断时癫痫风险为24.4%,无受累者为10.3%。
- 原发性运动皮层受累与诊断后癫痫风险升高相关(HR 1.95)。
- 不推荐在临床试验外对原发性运动皮层脑转移患者常规使用抗癫痫药物预防。
核心结论
- 原发性运动皮层脑转移患者可能表现出增加的癫痫风险。
- 鉴于研究为回顾性,不推荐在临床试验外对这类患者常规使用抗癫痫药物。
- 可能需要专门试验评估该人群的预防性抗癫痫药物使用。
研究设计与样本
- 回顾性队列研究,纳入2003至2022年布里格姆妇女医院/丹娜法伯癌症研究院数据库中有脑转移影像学证据的患者。
- 共纳入3043例患者,其中570例(18.7%)有原发性运动皮层脑转移,2473例(81.3%)无。
- 单发脑转移亚组分析纳入1174例患者。
- 使用单变量/多变量逻辑回归和Fine and Gray竞争风险回归评估原发性运动皮层受累对诊断时及之后癫痫风险的影响。
主要发现
- 原发性运动皮层脑转移患者诊断时癫痫发生率为24.4%,无受累者为10.3%(OR 2.87,95%CI 2.23-3.98,p<0.001)。
- 原发性运动皮层受累与诊断后癫痫风险升高相关(HR 1.95,95%CI 1.56-2.43,p<0.001)。
- 在1446例初始颅内肿瘤受累后发生额外脑转移的患者中,原发性运动皮层受累者后续发生癫痫的可能性更高(HR 2.11,95%CI 1.56-2.86,p<0.001)。
临床怎么用
- 临床应关注原发性运动皮层脑转移患者的癫痫风险,但不应在临床试验外常规预防性使用抗癫痫药物。
- 对于原发性运动皮层脑转移患者,可考虑密切监测癫痫发作,并个体化评估抗癫痫药物使用。
局限性
- 本研究为回顾性研究,存在回顾性设计固有的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Seizures are common in patients with brain metastases (BMs), causing significant morbidity and reduced quality of life. The relationship between BM location and seizure risk remains unclear. Nononcologic literature suggests that primary motor cortex disruption may predispose to seizures. This study evaluated whether BM in primary motor cortex display increased seizure risk relative to BM in other locations. METHODS: In this retrospective cohort study, patients with radiographic evidence of BM managed at Brigham and Women's Hospital/Dana-Farber Cancer Institute between 2003 and 2022, and maintained in a database, were included. Abstracted covariables spanned demographic (age, sex, and race), clinical (comorbidities and performance status), oncologic (cancer type, extracranial/intracranial disease extent, and prior systemic therapy), radiotherapeutic/neurosurgical (employment and type of radiation, presence of preceding brain-directed surgery), and outcome/seizure-related (presence, timing, and nature of seizures) domains. The exposure variable was BM in the primary motor cortex, and the outcome measure was seizures on a per-patient level. The effect of primary motor cortex involvement on seizure risk, at diagnosis and thereafter, was evaluated using univariable/multivariable logistic, and Fine and Gray competing risks regression, respectively. To limit confounding by lesion number, analyses were repeated in patients with a single BM at diagnosis (n = 1,174). RESULTS: Among 3,043 patients with (n = 570, 18.7%) vs without (n = 2,473, 81.3%) BM in primary motor cortex, the mean age was 60 vs 61 years, and 61% vs 62% of patients were female, respectively. Primary motor cortex involvement was associated with increased seizure risk at diagnosis (24.4% vs 10.3%, odds ratio 2.87, 95% CI 2.23-3.98, p < 0.001) and after initial diagnosis (hazard ratio [HR] 1.95, 95% CI 1.56-2.43, p < 0.001). Of 1,446 patients who developed additional BM after initial intracranial oncologic involvement, those with disease involving primary motor cortex were more likely to develop seizures thereafter (HR 2.11, 95% CI 1.56-2.86, p < 0.001). DISCUSSION: Patients with BM in the primary motor cortex may display increased seizure risk. As this study was retrospective, routine use of antiseizure medications in patients with BM in primary motor cortex in the off-trial setting is not recommended. However, dedicated trials evaluating prophylactic antiseizure medications in this population may be warranted.
引用
- Baselga-Garriga C, Purohit S, Lamba N, et al. Primary Motor Cortex Involvement and Its Association With Seizure Risk in Patients With Brain Metastases. Neurology. 2026. PMID: 41747204. doi:10.1212/WNL.0000000000214714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。